Alkermes PLC

Most Recent

  • uploads///blood _
    Earnings Report

    Alkermes in the Third Quarter: A Performance Overview

    Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.

    By Daniel Collins
  • uploads///Alkermes
    Company & Industry Overviews

    How’s Alkermes Positioned Financially in September?

    In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017.

    By Daniel Collins
  • uploads///NKTR
    Company & Industry Overviews

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).

    By Kenneth Smith
  • uploads///analysis _
    Company & Industry Overviews

    What Analysts Think of PolarityTE and Its Peers

    In June, PolarityTE stock has been given a “buy” rating by the one analyst covering it. The target price for the stock is $65.

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    Why Heron Therapeutics Rose 33% in Pre-Market Trading Today

    Heron Therapeutics (HRTX) stock surged after the company announced it had received breakthrough designation from the FDA for its postoperative pain management drug, HTX-011.

    By Sarah Collins
  • uploads///capsule _
    Company & Industry Overviews

    What’s the Upside Potential of Nektar Therapeutics?

    Of the 12 analysts covering Nektar Therapeutics in June 2018, 11 analysts have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///ALKS Aristada sales
    Company & Industry Overviews

    A Deeper Look at Alkermes’ Key Marketed Products

    Alkermes’ (ALKS) Aristada is an intramuscular injectable suspension for the treatment of schizophrenia.

    By Kenneth Smith
  • uploads///nerve cell _
    Company & Industry Overviews

    Analysts’ Ratings for Alkermes and Its Peers in February 2018

    Of the 12 analysts covering Alkermes (ALKS) in February, five analysts gave ALKS a “buy” rating. Seven analysts gave it a “hold” rating.

    By Kenneth Smith
  • uploads///ALKS
    Company & Industry Overviews

    A Look at Alkermes’ Diabetes Product Portfolio

    According to Alkermes, ~26.0 million people in the US and 382.0 million people globally are affected by diabetes.

    By Kenneth Smith
  • uploads///ALKS RD pipeline
    Company & Industry Overviews

    An Insight into Alkermes’ R&D Pipeline

    Alkermes’ ALKS3831 is an investigational oral medicine is targeted for the treatment of schizophrenia.

    By Kenneth Smith
  • uploads///ALKS
    Company & Industry Overviews

    Exploring Alkermes’ Financial Performance in Fiscal 2017

    Alkermes (ALKS) generated total revenues of $903.0 million in fiscal 2017 compared with $745.6 million in fiscal 2016.

    By Kenneth Smith
  • uploads///virus _
    Company & Industry Overviews

    Analyst Ratings for Vanda Pharmaceuticals and Peers in February

    Of the six analysts covering Vanda Pharmaceuticals in February 2018, two of them have given the stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Analyst Recommendations for Nektar Therapeutics in November 2017

    In 3Q17, Nektar Therapeutics (NKTR) reported revenues of $152.9 million, a YoY rise of 320.7%. The sudden spurt is mainly due to the upfront payment of $150 million from Eli Lilly.

    By Margaret Patrick
  • uploads///Fidelity Growth Company Fund
    Company & Industry Overviews

    This Sector Has Hurt the Fidelity Growth Company Fund so Far in 2016

    The Fidelity Growth Company Fund (FDGRX) places ninth in the YTD period among the group of 12 funds we’ve chosen for this review.

    By David Ashworth
  • uploads///Portfolio Breakdown of the FNGAX
    Fund Managers

    What’s the Sector Composition of the FNGAX?

    The Franklin International Growth Fund invests “in the equity securities of mid- and large-capitalization companies outside the U.S. with long-term growth potential.”

    By David Ashworth
  • uploads///Fidelity Growth Company Fund
    Company & Industry Overviews

    What’s Been Beating down the Fidelity Growth Company Fund in 2016?

    FDGRX has declined by 0.7% YTD (year-to-date) in 2016. This decline has led to the fund being among the below-average funds in our group of 12.

    By David Ashworth
  • uploads///Portfolio Breakdown of the FNGAX
    Fund Managers

    The Franklin International Growth Fund’s Portfolio Moves in YTD 2016

    In the past 12 months until May 2016, Franklin International Growth Fund (FNGAX) has witnessed increased exposure to discretionary and healthcare stocks.

    By David Ashworth
  • uploads///Part  Graph
    Company & Industry Overviews

    How Does XBI Compare to Its 100-Day Moving Average?

    The SPDR S&P Biotech ETF (XBI) rose marginally by 0.1% on April 20, 2016. Within XBI, Kite Pharma (KITE) closed at $48.98 on the day.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI News as of March 16: Mid-Caps Under Pressure

    Given selling pressures, XBI’s 18 mid-cap stocks went down marginally on average, losing 0.4% on March 16. Eight stocks advanced while ten stocks declined.

    By Peter Neil
  • uploads///FNGAXs Top Invested Geographies
    Fund Managers

    What You Should Know about the Franklin International Growth Fund

    The Franklin International Growth Fund – Class A (FNGAX) was incepted in June 2008 and has an expense ratio of 1.4%.

    By David Ashworth
  • uploads///Fidelity Growth Company Fund Vs Peers
    Company & Industry Overviews

    How Has the Fidelity Growth Company Fund Performed in 2016?

    The Fidelity Growth Company Fund (FDGRX) was among the top five largest funds in this peer group, managing assets worth $36.0 billion as of January 2016.

    By David Ashworth
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Alexion Continues to Rise on FDA’s Approval of Kanuma

    Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    How Are IBB’s American Depositary Receipts Performing?

    The ADRs of the iShares Nasdaq Biotechnology ETF (IBB) had negative returns of 1% for the week ended December 4, 2015. IBB provides good exposure to international biotech stocks.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Europe Approved Biogen’s Elocta, Topped XBI’s Large-Cap Stocks

    Biogen rose 1% on November 25. It closed at $292.30. It was trading 5.7% below the 100-day moving average price of $309.85. It passed the 20-day moving average.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Amgen Rises by 2% as XBI’s Large-Cap Stocks Rally

    Amgen closed at $157.60 and was trading above its 50- and 100-day moving averages. The stock also witnessed a rise in trading volumes.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    AbbVie, Lead Performer of the Pharmaceutical Subgroup

    AbbVie (ABBV) rose 18.3% for the week ended October 30, 2015, and closed at $59.55. The stock went up on good 3Q15 earnings.

    By Peter Neil
  • uploads///Graph
    Miscellaneous

    Alkermes’s Multi-Pronged Strategy for Its Aristada Launch

    Alkermes plans a multi-pronged strategy for Aristada’s successful launch, which will involve flexible usage, effective pricing, and additional research.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Alkermes’s Aristada and Its FDA Approval for Schizophrenia

    Aristada was approved by the FDA and is projected to account for 10% to 30% of the LAI atypical antipsychotic market for schizophrenia patients in the US.

    By Margaret Patrick
  • uploads///Graph Part
    Company & Industry Overviews

    Alnylam Up 2.0% on Phase 1 Initiation of OLE Study with ALT-AT3

    Alnylam Pharmaceuticals (ALNY) rose 2.0% on news that it has initiated a Phase I open-label extension (or OLE) study with ALN-AT3 for the treatment of hemophilia and rare bleeding disorders.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Akorn’s Revenue

    In 2014, prescription pharmaceuticals generated revenue of $542.84 million, and consumer health generated revenue of $50.23 million— 91.5% and 8.5% of total revenue, respectively.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Top Ten of XBI Outperform by Market Cap

    The average return of the top ten IBB stocks was -4.73%, while the average return of top ten XBI stocks was -3.89% for the week ended September 4, 2015.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Healthcare and Pharmaceuticals Prevail in Stable Market Conditions

    The healthcare sector and the pharmaceutical sector underperformed IBB, but outperformed the broader index SPY for the week ending July 31, 2015.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    What Led Large-Cap Stocks to Outperform Mid and Small Caps?

    Within the iShares Nasdaq Biotechnology ETF (IBB), for the week ending July 31, 2015, the top ten large-cap stocks had a weight of 56.59% of IBB’s portfolio.

    By Peter Neil
  • uploads///Part  chart
    Company & Industry Overviews

    Pharma Stocks Show a Positive Trend

    The upward trend in the pharmaceutical sector for the week ending July 17, 2015, was not caused by the oversold or overbought condition.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.